Skip to main content

Illinois IGB

David Kranz

Engineered immune cells recognize, attack solid-tumor cancer cells

July 1, 2020

A method known as CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia. It modifies a patient’s own T-cells by adding a piece of an antibody that recognizes unique features on the surface of cancer cells. In a new study, researchers report that they have dramatically broadened the potential targets of this approach – their engineered T-cells attack a variety of solid-tumor cancer cells from humans and mice.


July 1, 2020


Related Articles

Subscribe to David Kranz